BSH 2023 | Shifting the treatment landscape of ITP: novel agents and future outlooks
David Kuter, MD, DPhil, Massachusetts General Hospital, Boston, MA, comments on the current shift in treatment approaches for patients with immune thrombocytopenia (ITP). Prof. Kuter explains that medications such as rituximab and thrombopoietin (TPO) receptor agonists should be used more frequently to treat newly diagnosed ITP, and further suggests that older treatment approaches, such as corticosteroids and splenectomy, should be reduced or avoided entirely. Prof. Kuter concludes by highlighting promising novel agents currently being tested in newly diagnosed and refractory ITP. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research: Alnylam, Biocryst, Novartis, Rigel, Sanofi (Principia), Takeda (Bioverativ), UCB
Consulting: AIRx, Alexion (Syntimmune), Alnylam, Alpine, Amgen, Argenx, BioCryst, Bristol Myers Squibb (BMS), Caremark, Cellularity, Cellphire, Chugai, CRICO, Daiichi Sankyo, Dianthus, Electra Therapeutics, Fuji, Hemopure, Hengrui. Immunovant, Incyte, Inmagenebio, Kezar, Kyowa-Kirin, Merck Sharp Dohme, Momenta, Novartis, Nuvig, Pfizer, Platelet Biogenesis, Platelet Disorder Support Association, Protagonist, Rigel, Sanofi (Bioveratif), Sanofi (Principia). Sanofi (Genzyme), Sobi (Dova), Takeda, UCB, Up-To-Date, Zafgen
Stock ownership: Rubius
